Saturday, August 2, 2025 8/2/2025

Development of a Peptide Therapy for Corneal Wound Healing

Award Number: R41EY034062
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2025

Group Awards By:

View Award Description

Development of a Peptide Therapy for Corneal Wound Healing - PROJECT SUMMARY/ABSTRACT Acute corneal epithelial injuries (corneal abrasions, foreign bodies, contact lens related injuries) are extremely common (more than 1 million per year). Injuries like corneal abrasions may lead to downstream consequences like corneal infections and inflammation, vision loss, and chronic wounds. Very limited interventions are currently available for these wounds. The standard of care for mild acute injuries is primarily supportive, with antibiotics given topically to prevent infectious complications. Severe cases may require ocular device placement, like amniotic membrane containing contact lenses, or even surgery. During the recovery time, patients suffer from pain, reduced vision and difficulty working and performing activities of daily living. The proposed work supports the development of a first-in-class, peptide-based, topical eye drop to accelerate the recovery time and allow patients to return to function sooner. This peptide therapy has a different mechanism of action than other eye drops given for ocular surface diseases. The objective of this Phase I STTR is to derisk the development of this novel therapy through two Aims (1) testing efficacy in in vivo models of disease and (2) determination of ideal parameters for drug application. The proposed research is innovative as it is the first study to investigate the use of these peptides in critical derisking drug development models. These studies are significant because they will advance the development of a new therapeutic through the use of rigorous and well-defined methods in clinically relevant translational models of disease and serve as the basis for later stages of development to bring this therapy to patients. Success will be determined by efficacy testing above a clinically relevant threshold for improvement and establishment of critical dosing parameters. Phase II follow on studies would include 28-day toxicological testing, formulation development, chemistry- manufacturing-control (CMC) studies and scale up of peptide production for subsequent clinical trials. The results of these experiments will support an Investigational New Drug (IND) application to the Food and Drug Administration (FDA).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2022	VISO THERAPEUTICS INC.	2256 WENDT CIR	NAPERVILLE	IL	60564	WILL	USA	Vision Research	000	1	11/6/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	VISO THERAPEUTICS INC.	512 N MCCLURG CT APT 3601	CHICAGO	IL	60611	COOK	USA	Vision Research	000	1	11/2/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $300,889 )
2022	2022	VISO THERAPEUTICS INC.	512 N MCCLURG CT APT 3601	CHICAGO	IL	60611	COOK	USA	Vision Research	000	1	8/24/2022	NEW	$300,889
														Subtotal = $300,889

Grand Total All Awards = $300,889

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of a Peptide Therapy for Corneal Wound Healing

Award Number: R41EY034062

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer